When Myeloma Returns: Navigating Treatment After 1–3 Prior Lines

When multiple myeloma returns after 1–3 prior lines of therapy, treatment decisions become more complex and highly individualized. In this HealthTree video, we break down what relapsed or refractory multiple myeloma means and explore the evolving treatment landscape available to patients at earlier stages of relapse. Learn about current standard-of-care options, including immunomodulatory drugs, proteasome inhibitors, monoclonal antibodies, and emerging therapies such as bispecific antibodies and CAR-T cell therapy. We also discuss how clinicians choose next-line treatments based on prior response, disease biology, and patient-specific factors. Whether you are a patient, caregiver, or healthcare professional, this video provides clear, up-to-date insights to help you better understand treatment pathways after early relapse in multiple myeloma. 0:00 Introduction 0:27 What treatment options are available for patients who have relapsed after 1-3 lines of therapy? 3:48 How does the upfront use of daratumumab impact its use at relapse? 5:35 Should all patients receive CAR-T therapy at first relapse? 8:40 How are bispecific antibodies being used in earlier lines of therapy? 10:30 Is there a role for selinexor in the earlier lines of therapy? 11:17 Is t here a role for alkylating agents in this population? 12:12 Can a PACE based protocol be used? 14:04 What factors should be considered when choosing a treatment at relapse? 15:43 Conclusion If this video has helped you or a loved one, consider donating to HealthTree. Every donation helps us continue to create free and high-quality blood cancer educational content: https://give.healthtree.org/give/6286... For an organized lesson structure, watch on our site here: https://linktr.ee/HealthTreeUniversity Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer! Patients have the key to find cures for cancer. Learn more about HealthTree's services here: https://healthtree.org/curehub?utm_so... Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.